NewAmsterdam Pharma Announces Participation at Investor Events in September

NAARDEN, The Netherlands, and MIAMI, August 30, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a pivotal player in the biopharmaceutical sector focussed on developing innovative oral treatments for cardiovascular diseases, has officially confirmed its participation in a series of investor conferences planned for September. These conferences are integral for NewAmsterdam to discuss its late-stage clinical pipeline and share updates on the progress of its non-statin drug candidates aimed at addressing the unmet needs in cardiovascular health.

Investor Conferences as a Platform for Progress

Investor conferences serve as a vital platform for NewAmsterdam to not only attract potential investment but also to provide detailed explanations of their clinical advancements and strategic vision. The engagement with investors, analysts, and other industry specialists will be an important opportunity for NewAmsterdam to strengthen its industry position and highlight its commitment to innovation in tackling cardiovascular risks through orally administered treatments.

A Firm Standing in the Investment Community

With an expectation to engage with a diverse pool of attendees, NewAmsterdam aims to solidify its reputation in the investment community. Their presence at these events is anticipated to be a strong signal of their growth trajectory and the potential for their investigational therapies. The Company's inclusion in notable conferences also suggests confidence in their approach, which could potentially attract the attention of more investors, such as those associated with Morgan Stanley MS, a leading global financial services firm recognized for its investment expertise.

investment, biopharmaceutical, cardiovascular